Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly Earnings: Robust Growth Lifted by Broad Portfolio Strength, Especially Mounjaro While the firm is well-positioned for growth, we believe the market is overly optimistic about its outlook.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly's operating income rose by 75%. For the three-month period ended June 30, Lilly's revenue increased by 36% year over year to $11.3 billion, thanks in large part to the growth in Mounjaro ...

Eli Lilly and Company LLY reported second-quarter 2023 adjusted earnings per share of $2.11, which beat the Zacks Consensus Estimate of $1.98.

Eli Lilly not only beat earnings per share (EPS) expectations with a non-GAAP EPS of $2.58 compared to the analysts' consensus figure of $2.47, but also showcased an impressive revenue increase.

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

Eli Lilly's operating income rose by 75%. For the three-month period ended June 30, Lilly's revenue increased by 36% year over year to $11.3 billion, thanks in large part to the growth in Mounjaro ...